Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug.
Kuuliala A, Leirisalo-Repo M, Möttönen T, Hannonen P, Nissilä M, Kautiainen H, Korpela M, Julkunen H, Hakola M, Repo H; FIN-RACo Trial Group. Kuuliala A, et al. Among authors: korpela m. Clin Exp Rheumatol. 2005 Mar-Apr;23(2):243-6. Clin Exp Rheumatol. 2005. PMID: 15895898 Clinical Trial.
Polymorphism at position +896 of the toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritis.
Kuuliala K, Orpana A, Leirisalo-Repo M, Kautiainen H, Hurme M, Hannonen P, Korpela M, Möttönen T, Paimela L, Puolakka K, Karjalainen A, Repo H. Kuuliala K, et al. Among authors: korpela m. Ann Rheum Dis. 2006 Sep;65(9):1241-3. doi: 10.1136/ard.2006.055137. Epub 2006 Apr 10. Ann Rheum Dis. 2006. PMID: 16606645 Free PMC article. Clinical Trial.
Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis.
Laivoranta-Nyman S, Möttönen T, Hannonen P, Korpela M, Kautiainen H, Leirisalo-Repo M, Julkunen H, Luukkainen R, Hakala M, Vuori K, Laine AP, Toivanen A, Ilonen J; FIN-RACo Trial Group. Laivoranta-Nyman S, et al. Among authors: korpela m. Clin Exp Rheumatol. 2006 Nov-Dec;24(6):636-42. Clin Exp Rheumatol. 2006. PMID: 17207378 Clinical Trial.
Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression.
Hakala M, Risteli J, Aman S, Kautiainen H, Korpela M, Hannonen P, Leirisalo-Repo M, Laasonen L, Paimela L, Möttönen T; Fin-Raco Trial Group. Hakala M, et al. Among authors: korpela m. Scand J Rheumatol. 2008 Mar-Apr;37(2):90-3. doi: 10.1080/03009740701753689. Scand J Rheumatol. 2008. PMID: 18415764 Clinical Trial.
Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
Mustila A, Korpela M, Haapala AM, Kautiainen H, Laasonen L, Möttönen T, Leirisalo-Repo M, Ilonen J, Järvenpää S, Luukkainen R, Hannonen P. Mustila A, et al. Among authors: korpela m. Clin Exp Rheumatol. 2011 May-Jun;29(3):500-5. Epub 2011 Jun 29. Clin Exp Rheumatol. 2011. PMID: 21640044 Clinical Trial.
180 results